On 19 August 2021, Oslo Børs resolved to impose violation charge on Aker
BioMarine ASA, totaling NOK 500,000 for breach of the duty to disclose inside
information and for breach of the duty to provide information to Oslo Børs.

Oslo Børs has passed the following decision:

"For significant breach of the duty to disclose inside information to the market
pursuant to Continuing Obligations section 3.1.1 (1), a violation charge is
imposed on Aker BioMarine ASA of NOK 350,000, cf. Continuing Obligations section
12.3 (2) and (3).

For significant breach of the duty to provide Oslo Børs with information upon
request pursuant to Continuing Obligations section 2.5 (4), a violation charge
is imposed on Aker BioMarine ASA of NOK 150,000, cf. Continuing Obligations
section 12.3 (2) and (3)."

A brief summary of the case:

On 24 November 2020, Aker BioMarine announced the launch of Lysoveta as a new
business segment for the company. Oslo Børs considers that this information
constituted inside information no later than in the evening of 19 November 2020
and that the duty to disclose the inside information arose at the same time.
Furthermore, Aker BioMarine has breached its duty to provide information to Oslo
Børs by not providing the exchange with information about certain matters in
connection with the exchange's inquiries about the matter.

Click here for more information

© Oslo Bors ASA, source Oslo Stock Exchange